Amgen Pleads Guilty to Misbranding Anemia Drug Aranesp

Amgen Pleads Guilty to Misbranding Anemia Drug Aranesp

Amgen via Bloomberg

Amgen Inc., the world’s largest biotechnology company, pleaded guilty to misbranding its anemia medication Aranesp and agreed to pay $762 million in criminal penalties and civil settlements.